Hsbc Holdings PLC Increases Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Hsbc Holdings PLC increased its stake in Medpace Holdings, Inc. by **157.5%**, acquiring an additional **2,669 shares**, bringing its total holdings to **4,364 shares** valued at approximately **$1.3 million**.
• Analysts have given mixed ratings on Medpace stock, with **two buy ratings, nine hold ratings,** and **three sell ratings**, while price targets vary significantly from **$305 to $450**.
• Medpace reported **$3.10 earnings per share** in its last quarterly results, exceeding estimates and reflecting a **14.2% year-over-year revenue growth** to **$603 million**.

Hsbc Holdings PLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 157.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,364 shares of the company's stock after buying an additional 2,669 shares during the period. Hsbc Holdings PLC's holdings in Medpace were worth $1,296,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MEDP. Giverny Capital Inc. increased its holdings in shares of Medpace by 7.5% during the 1st quarter. Giverny Capital Inc. now owns 251,937 shares of the company's stock worth $76,763,000 after buying an additional 17,650 shares during the last quarter. Northern Trust Corp grew its position in Medpace by 36.0% in the first quarter. Northern Trust Corp now owns 337,489 shares of the company's stock worth $102,830,000 after acquiring an additional 89,347 shares during the period. Brooklyn Investment Group increased its stake in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after acquiring an additional 71 shares during the last quarter. Versor Investments LP purchased a new stake in Medpace in the first quarter valued at $487,000. Finally, Algert Global LLC lifted its stake in shares of Medpace by 18.4% in the 1st quarter. Algert Global LLC now owns 49,918 shares of the company's stock valued at $15,210,000 after purchasing an additional 7,761 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $342.00 to $474.00 in a research report on Wednesday. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Barclays increased their price objective on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their target price for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace has a consensus rating of "Reduce" and an average target price of $412.73.

Insider Buying and Selling

In other news, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the completion of the transaction, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 151,266 shares of company stock worth $69,311,427 over the last ninety days. Company insiders own 20.30% of the company's stock.

Medpace Stock Up 0.2%

Medpace stock traded up $1.11 during mid-day trading on Thursday, reaching $482.34. 252,691 shares of the company's stock were exchanged, compared to its average volume of 316,973. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The company has a market cap of $13.55 billion, a P/E ratio of 35.86, a P/E/G ratio of 3.03 and a beta of 1.44. The company has a fifty day moving average of $409.16 and a 200-day moving average of $343.18.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.